Research Analysts’ Weekly Ratings Updates for iBio (IBIO)

Several analysts have recently updated their ratings and price targets for iBio (NASDAQ: IBIO):

• 3/18/2026 – iBio had its “buy” rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock.
• 3/3/2026 – iBio is now covered by JonesTrading. They set a “buy” rating and a $7.00 price target on the stock.
• 3/2/2026 – iBio was upgraded by JonesTrading to “strong-buy”.
• 2/28/2026 – iBio was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/14/2026 – iBio was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/12/2026 – iBio had its “buy” rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock.

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.